1. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort
- Author
-
Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Gherasim, Alin, Brytting, Mia, Domegan, Lisa, Gomez, Veronica, Meijer, Adam, Lazar, Mihaela, Vucina, Vesna Visekruna, Duerrwald, Ralf, van der Werf, Sylvie, Larrauri, Amparo, Enkirch, Theresa, O'Donnell, Joan, Guiomar, Raquel, Hooiveld, Mariette, Petrovic, Goranka, Stoian, Elena, Penttinen, Pasi, Valenciano, Marta, Preuss, Ute, Tolksdorf, Kristin, Biere, Barbara, Smallfield, Maria, Wedde, Marianne, Falchi, Alessandra, Masse, Shirley, Villechenaud, Natacha, Souty, Cecile, Blanchon, Thierry, Launay, Titouan, Enouf, Vincent, Behillil, Sylvie, Lina, Bruno, Valette, Martine, Mazagatos, Clara, Casas, Inmaculada, Garcia Comas, Luis, Insua Marisquerena, Maria Esther, Carlos Galan, Juan, Castilla, Jesus, Garcia Cenoz, Manuel, Navascues, Ana, Quinones Rubio, Carmen, Ibanez Perez, Ana Carmen, Martinez Ochoa, Eva, Blasco, Miriam, Gimenez Duran, Jaume, Maria Vanrell, Juana, Reina, Jordi, Castrillejo, Daniel, Wiman, Asa, Hunt, Meadhbh, Joyce, Michael, Levis, Olga, Collins, Claire, Dunford, Linda, Bennett, Charlene, Moran, Joanne, Tuite, Grainne, Connell, Jeff, de Gascun, Cillian, Rodrigues, Ana Paula, Machado, Ausenda, Nunes, Baltazar, Kislaya, Irina, Costa, Ines, Conde, Patricia, Cristovao, Paula, Pechirra, Pedro, Borges, Vitor, Bagheri, Mariam, van den Brink, Sharon, Dijkstra, Frederika, Goderski, Gabriel, van der Hoek, Wim, de Lange, Marit, Marzec, Ton, Overduin, Pieter, Reukers, Daphne, Teirlinck, Anne, Wijsman, Lisa, Donker, Ge, Mihai, Maria Elena, Cherciu, Carmen Maria, Alexandrescu, Viorel, Kaic, Bernard, Filipovic, Sanja Kurecic, Novosel, Iva Pem, Makaric, Zvjezdana Lovric, Zajec, Martina, Drazenovic, Vladimir, Moren, Alain, I-MOVE Primary Care Study Team, EpiConcept [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), and Netherlands Institute for Health Services Research [Utrecht] (NIVEL)
- Subjects
vacunas de la gripe ,Male ,0301 basic medicine ,potencia vacunal ,Epidemiology ,[SDV]Life Sciences [q-bio] ,humanos ,Gripe ,adolescente ,Hemagglutinin Glycoproteins, Influenza Virus ,virus de la influenza A ,0302 clinical medicine ,infecciones del tracto respiratorio ,memoria inmunológica ,vigilancia centinela ,Determinantes de Saúde e Doença ,Medicine ,030212 general & internal medicine ,Respiratory Tract Infections ,mediana edad ,Vaccine effectiveness ,anciano ,birth cohorts ,Birth cohorts ,Estado de Saúde e Doença ,resultado del tratamiento ,Vaccination ,Age Factors ,Imprinting ,adulto ,Middle Aged ,multicentre study ,Europe ,Treatment Outcome ,Influenza A virus ,Época 2018-2019 ,Influenza Vaccines ,Population Surveillance ,Female ,Seasons ,imprinting ,influenza ,Birth cohort ,A(H3N2) ,Adult ,Adolescent ,Primary care ,Multicentre study ,vacunación ,03 medical and health sciences ,vigilancia de la población ,Virology ,Influenza, Human ,Humans ,ddc:610 ,Vacina Antigripal ,EuroEVA ,Vaccine Potency ,Aged ,vaccine effectiveness ,business.industry ,Influenza A Virus, H3N2 Subtype ,Research ,Efetividade ,Public Health, Environmental and Occupational Health ,Influenza a ,Influenza ,estaciones (meteorología) ,030104 developmental biology ,influenza vaccination, test negative case control, vaccine effectiveness ,610 Medizin und Gesundheit ,business ,Immunologic Memory ,Sentinel Surveillance ,Demography - Abstract
Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-year-olds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study.
- Published
- 2019
- Full Text
- View/download PDF